|
|
Article: Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India.
- Article from:
- PR Newswire
- Article date:
- October 28, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
- State of the art 25,000 sq. ft. facility to be operational in 4 months - 60 million doses of annual vaccine capacity anticipated
ROCKVILLE, Md., Oct. 28 /PRNewswire-FirstCall/ -- Novavax, Inc. announced today that CPL Biologicals Pvt. Ltd., the new joint venture between Cadila Pharmaceuticals in India, has begun construction of a state-of-the-art manufacturing facility that will be used to produce pandemic and seasonal influenza vaccines. CPL Biologicals will utilize Novavax's virus-like particle (VLP) vaccine technology to produce commercial-scale quantities of VLP-based influenza vaccines using Novavax's innovative disposable manufacturing solution. The CPL ...
Related newspaper, magazine, and journal articles:
|
|
Article: Novavax secures $11 million investment from Cadila ...
Datamonitor Financial Deals Tracker;
April 3, 2009 ;
700+ words
... ... of its common stock to a wholly-owned subsidiary of Cadila Pharmaceuticals, Ltd., an India-based pharmaceutical company ... Target (Company) Novavax, Inc. Acquirer (Company) Cadila Pharmaceuticals Limited Deal Rationale Novavax intends to use the proceeds ...
|
|